All Drug Targets articles
-
ArticleInside one of the most comprehensive human proteome atlases to date
Understanding where proteins are expressed throughout the body is critical for selecting better drug targets. Here’s how a new human proteome atlas could improve target selection, predict toxicity and support drug repurposing.
-
NewsHow dendritic cells organise tumour immunity – and why drug developers should take notice
A new study published in Science identifies a specialised dendritic cell subset as the cellular architects behind tertiary lymphoid structures, offering a potential new target for boosting anti-tumour immunity and converting immunologically cold tumours into treatment-responsive ones.
-
NewsLandmark fibromyalgia study highlights neurological targets for new therapies
A landmark genome-wide study of more than 2.5 million adults has identified 26 genomic regions linked to fibromyalgia, confirming a neurological basis for the condition and opening new avenues for targeted drug discovery.
-
WebinarOligonucleotide therapeutics safety considerations across drug development
As oligonucleotide therapeutics rapidly advance, their safety profile presents challenges unlike any other drug modality. Discover how nonclinical safety studies, regulatory expectations and real-world case examples can help you navigate these challenges with greater confidence.
-
NewsAmino acid sensor discovery could unlock new targeted cancer therapies
Researchers have uncovered how cells sense amino acids and activate the mTORC1 growth pathway, identifying LARS1 phosphorylation as a critical upstream switch with implications for more precise cancer drug development.
-
News3D genome reorganisation identified as Alzheimer’s disease molecular hallmark
An international study combining single-cell genomics, spatial transcriptomics and artificial intelligence has identified large-scale changes in three-dimensional genome organisation in Alzheimer’s-affected brain cells, establishing chromatin architecture as a previously overlooked component of the disease’s molecular pathology and a potential framework for future therapeutic targeting.
-
NewsInsilico Medicine nominates ISM9528 non-opioid chronic pain candidate using AI
Insilico Medicine has nominated ISM9528, an orally available, brain-penetrant non-opioid candidate targeting a previously unrecognised pain mechanism, as its 31st AI-generated preclinical compound since 2021, with efficacy exceeding morphine in some preclinical models.
-
NewsNew drug target identified to protect hearts in DMD patients
Researchers at the University of South Florida have identified NOX4 as a potential therapeutic target for DMD-related cardiomyopathy, with experimental drug Setanaxib demonstrating cardioprotective effects in preclinical models.
-
WebinarMeeting ethical & regulatory requirements when using human biological specimens
Whether you source, purchase or work with human biospecimens, understanding today’s ethical and regulatory expectations is essential. Join this webinar to explore informed consent, privacy and the principles that support responsible research.
-
ArticleHow AI and human biology data led to a new addiction drug candidate
How can human biology data improve target selection? Learn how one discovery programme identified a potential new treatment for opioid use disorder.
-
NewsPCSK9 peptide vaccine lowers LDL cholesterol in preclinical studies
A structure-guided peptide vaccine targeting PCSK9 has demonstrated durable antibody responses and reduced LDL cholesterol levels in mouse models of hypercholesterolaemia, offering a potential long-lasting alternative to current lipid-lowering therapies.
-
NewsVitronectin protein identified as key driver of lung scarring
Researchers from UTS and Monash University have identified vitronectin as a key protein driving abnormal lung scarring in idiopathic pulmonary fibrosis, opening a potential new avenue for therapeutic intervention in a disease with very few treatment options.
-
NewsPancreas organoids reveal CFTR dysfunction as chronic pancreatitis drug target
Researchers at the Salk Institute have developed a patient-derived organoid platform that identifies distinct biological subtypes of chronic pancreatitis and highlights CFTR as a potential therapeutic target, raising prospects for more personalised treatments.
-
NewsNTX-301 targets treatment-resistant AML via Hippo pathway in preclinical study
A novel epigenetic therapy has demonstrated activity against treatment-resistant acute myeloid leukaemia in preclinical models, including high-risk TP53-mutant disease, by selectively reactivating the Hippo tumour-suppressor pathway.
-
NewsNew BET therapies could help beat resistance in solid cancers
A new review finds that next-generation BET-targeted therapies, including selective inhibitors and PROTACs, are addressing the clinical shortcomings of earlier compounds and reviving interest in this approach for solid tumour treatment.
-
NewsAUTAC strategy targets MCL1 to overcome myeloma treatment resistance
Scientists at VCU Massey Comprehensive Cancer Center have developed an autophagy-targeting chimera that redirects cancer cells’ own recycling machinery to degrade the survival protein MCL1, offering a potential new strategy to overcome treatment resistance in multiple myeloma.
-
WebinarBuilding better therapeutic antibodies: the science, progress and problems to solve
As therapeutic antibodies become more complex, where is the field making real progress and which problems are proving hardest to solve? Hear leading experts share their perspectives.
-
ArticleOrgan chips move closer to drug discovery pipelines
From uncovering new drug targets to predicting human toxicity, organ chips are showing what they could bring to drug discovery. Professor Donald Ingber of Harvard University discusses where the technology is heading next.
-
NewsKCL-286 targets multiple Alzheimer’s pathways in preclinical study
A repurposed small molecule originally developed for spinal cord injury has demonstrated the ability to address multiple disease-relevant pathways in Alzheimer’s disease, including DNA damage and neuroinflammation, offering a potential route to disease-modifying therapy.
-
News15-PGDH enzyme inhibition protects brain cells in Parkinson’s disease models
Researchers have identified 15-PGDH enzyme inhibition as a neuroprotective strategy in Parkinson’s disease, with repurposable compounds already in clinical development offering a potential shortcut to disease-modifying therapies.